Engineered immunosuppressive dendritic cells protect against cardiac remodelling

A study published in Nature demonstrates that engineered immunosuppressive dendritic cells can protect against cardiac remodelling. Lesion-targeted immune modulation is identified as a feasible strategy to control cardiac fibrosis, with engineered dendritic cells emerging as a promising therapeutic platform for treating cardiac remodelling and heart failure.